Browse the evidence

Energy restriction is not supported by scientific evidence for improving glycemic control in Japanese patients with type 2 diabetes.

Current evidence does not support energy restriction as an effective standalone strategy for improving blood sugar in Japanese patients with type 2 diabetes, as studies show little to no benefit compared to other approaches.

A single-administration self-boosting microneedle patch delivering semaglutide sustains therapeutic plasma levels and induces weight loss in rats for one month, effectively simulating four separate weekly subcutaneous injections.

This research proposes a microneedle patch that delivers semaglutide (a weight-loss drug) through the skin. Instead of getting a shot every week, you apply a small patch once, and it releases the medication slowly over four weeks. In rats, this worked just as well as getting four separate shots. While promising for reducing pain and improving adherence, this is still experimental technology tested only on animals, not yet available for human use.

Controlled metabolic accelerators (CMAs) like HU6 induce weight loss via increased mitochondrial energy expenditure (uncoupling) rather than caloric restriction, resulting in fat loss while sparing skeletal muscle mass in patients with obesity-related HFpEF.

This paper describes a new class of drugs (CMAs) that burn fat by speeding up metabolism rather than restricting food. In early studies, this approach reduced fat mass significantly while keeping muscle mass stable, unlike diet or surgery which often weaken patients. This trial tests if this works for heart failure patients with obesity. It is not a lifestyle intervention but a pharmaceutical one requiring medical supervision.

Precision nutrition strategies, including monitoring postprandial glycemic responses and gut microbiome composition, may attenuate unfavorable cardiovascular risk factors associated with menopause.

Consider how your body responds to specific foods after eating (postprandial response). While full precision nutrition testing may not be available, focusing on fiber, reducing sugar, and potentially incorporating isoflavone-rich foods (like soy) may support gut health and metabolic stability during menopause.

Human observational studies on MSG and obesity show inconsistent results, with some finding positive associations and others finding no association or inverse associations, largely due to measurement errors and confounding factors.

Human studies on MSG and weight are mixed. While animal studies suggest risks, human data is not conclusive. Reducing intake of processed foods with hidden MSG is a low-risk strategy for overall health.

GLP-1 agonist administration in Type 1 Diabetes patients can precipitate Euglycemic Diabetic Ketoacidosis (EDKA) by suppressing gluconeogenesis and glycogenolysis, masking the hyperglycemia typically required for DKA diagnosis.

If you have Type 1 Diabetes and are taking a GLP-1 agonist (like Wegovy or Ozempic), be aware that you can develop Diabetic Ketoacidosis (DKA) even if your blood sugar looks normal. This is called Euglycemic DKA. If you experience nausea, vomiting, or abdominal pain, do not assume it is just a side effect or that your insulin is working. Check your blood ketones and seek medical attention if they are elevated, as standard DKA treatments (high insulin, no dextrose) may be dangerous without dextrose support.

Dietary fatty acid composition (specifically the n6/n3 ratio) influences fat oxidation and insulin response, with obese individuals showing higher carbohydrate oxidation and greater insulin response when consuming sunflower oil compared to canola oil.

If you are obese, be mindful of the types of oils you consume. Switching from sunflower oil to canola oil might improve your body's ability to burn fat and reduce insulin spikes, as obese individuals showed higher carbohydrate oxidation and greater insulin response with sunflower oil.

Childhood stunting is associated with altered metabolic profiles in adulthood, including lower fasting insulin, higher insulin sensitivity, and abnormal beta cell function, which may predispose stunted individuals to obesity and insulin resistance later in life.

For parents in low-resource settings, addressing childhood stunting is crucial not just for height, but for long-term metabolic health. Stunted children may have altered insulin sensitivity and beta cell function, increasing their risk of obesity and diabetes later in life.

Chronic stimulation of pancreatic beta-cells by incretin agonists may lead to beta-cell exhaustion, receptor downregulation, and potentially beta-cell failure over the long term.

While generally safe, long-term use of incretin medications may theoretically stress pancreatic beta-cells. Doctors monitor for this, but the long-term human data is still being gathered. It is important to discuss any concerns about long-term safety with your healthcare provider.

Modern obesogenic environments (sedentary lifestyle, high-calorie processed food) exploit evolutionary adaptations (brain expansion, efficient fat storage) leading to a 'normalization' of obesity phenotypes and genotypes.

Your environment is shaping your biology. To combat obesity, you must actively create a 'non-obesogenic' environment (healthy food access, physical activity) because your evolutionary biology is wired to store fat in such settings.

Chronic GIPR agonism may lead to desensitization that mimics functional antagonism, potentially explaining why both agonists and antagonists result in weight loss.

There is a theoretical possibility that long-term use of GIP-activating drugs could lead to receptor desensitization, acting like a blocker. However, current clinical evidence does not strongly support this in the brain, and these drugs remain effective for weight loss. Monitor your progress with your doctor.

Unimolecular tetra-receptor agonists (TC4) simultaneously activate GLP-1R, GIPR, GcgR, and Y2R, resulting in superior metabolic efficacy (weight loss and glycemic control) compared to mono- or dual-agonists by leveraging synergistic receptor engagement.

This research describes a new class of peptide drugs that target four metabolic receptors (GLP-1, GIP, Glucagon, and PYY) simultaneously. In preclinical studies, this approach showed strong potential for treating obesity and type 2 diabetes with fewer side effects like nausea than older drugs. It is not yet available for human use.

Tirzepatide administration is associated with novel postmarketing adverse events including palpitations, musculoskeletal pain, and headaches, which were not prominent in initial clinical trials.

If you experience palpitations, muscle pain, or headaches after starting Tirzepatide, report these to your doctor. These are not the typical stomach issues and may require dose adjustment or injection site changes.

South Asian ethnicity is predisposed to 'thin-fat' obesity (normal weight obesity), leading to higher risks of diabetes, hypertension, and dyslipidemia at lower BMIs.

If you are South Asian, your risk for diabetes and heart disease starts at a lower weight than other ethnicities. Even if your BMI is normal, you might have 'thin-fat' obesity. Get regular check-ups for blood sugar, blood pressure, and cholesterol, and focus on building muscle and staying active.

Tirzepatide, a dual GLP-1/GIP receptor agonist, may modify the natural course of lipedema by targeting its underlying immunometabolic, inflammatory, and fibrotic pathophysiology, rather than solely reducing body weight.

If you have lipedema, especially with insulin resistance, talk to your doctor about tirzepatide. It’s not just for weight loss; it may help reduce the inflammation and fibrosis causing your pain and stiffness. Since it’s a newer treatment for lipedema, ask about clinical trials or off-label use if appropriate for your case.

An automatic remote weight management system using smart scales and cloud-based dashboards can effectively monitor treatment response and identify early deviations from weight trajectories without increasing patient burden.

Using a smart scale that automatically uploads data to your doctor's dashboard can help catch weight regain early without you having to do extra work. This tool helps your care team prioritize who needs help, potentially keeping you on your medication and avoiding unnecessary visits.

GLP-1 RAs are associated with an increased risk of suicidal behavior and self-harm, particularly in patients with underlying mental health vulnerabilities or dysphoria.

If you are taking Semaglutide and experience mood changes, depression, or suicidal thoughts, contact your healthcare provider immediately. Do not ignore these symptoms. Regular screening for mental health is recommended for all patients on this medication.

Creatine supplementation trends toward increasing lean muscle mass in prostate cancer patients undergoing ADT.

Creatine supplementation may help preserve lean muscle mass in prostate cancer patients on hormone therapy, though the evidence is not yet definitive. It is worth discussing with your healthcare provider as a potential supportive measure.

Bariatric surgery (Roux-en-Y gastric bypass or sleeve gastrectomy) is technically feasible and safe for patients with pre-existing ileostomy or colostomy, without causing increased ostomy output or dehydration.

If you have an existing ostomy (ileostomy or colostomy) and are considering bariatric surgery, current preliminary evidence suggests it is feasible and safe, with no increased risk of dehydration or output changes compared to patients without an ostomy. Consult with a bariatric surgeon to evaluate your specific case, as individual factors like the cause of your ostomy and overall health status will determine your candidacy.

In the US, higher nutrition knowledge (better discernment of healthy vs. unhealthy foods) is positively associated with higher BMI.

Knowing what is healthy doesn't automatically lead to weight loss. This study found that in the US, people with higher nutrition knowledge had higher BMI, likely because knowledge alone doesn't overcome environmental or social barriers. Don't blame yourself for not losing weight despite knowing the facts. Focus on practical strategies to navigate your environment, not just on learning more about food.

In the US, higher food insecurity is inversely associated with BMI.

If you are experiencing food insecurity, you may find your weight is lower than expected. This study suggests that in the US, food insecurity is linked to lower BMI, likely due to limited access to food. If you are struggling to afford food, prioritize nutrient-dense, affordable options and seek community resources. Your health is important, and help is available.

Incretin-based therapies may attenuate intestinal iron absorption, independent of reduced intake, potentially contributing to iron deficiency in susceptible individuals.

Monitor iron levels if you have a history of anemia or low iron, as semaglutide may slightly reduce absorption.

Heterozygous variants in the POMC gene (specifically p.Arg90His, p.Ser94Gly, p.Ser94=, and p.Ala195=) are associated with an intermediate obesity phenotype in adults, likely due to haploinsufficiency affecting melanocortin peptide processing.

If you carry a heterozygous POMC variant, you may have an intermediate form of genetic obesity that responds differently to standard interventions. This information can help tailor your treatment plan, though functional validation of specific variants is still needed.

Tirzepatide as an adjunct to insulin in adults with Type 1 Diabetes and overweight/obesity produces significant body weight reduction and reduced insulin requirements, but current evidence is insufficient to establish durable glycaemic benefit or long-term safety.

For adults with Type 1 Diabetes and obesity, Tirzepatide is a promising tool for significant weight loss and reducing insulin needs. However, it is not yet proven to reliably improve long-term blood sugar control or safety. If used, it requires careful monitoring for side effects like nausea and potential risks like DKA, especially if insulin is reduced too aggressively. It is currently an investigational option, not a standard of care.